Decision-Making and Process

Regardless of your company or drug development stage, congress events are critical undertakings; they represent both a substantial opportunity and a significant investment of time and resources. These events provide an occasion to engage with a wide range of HCPs (including KOLs) to introduce new products, present data, gather insights, and more. Depending on your role in the company, the objectives that get you excited about attending one of these meetings will vary — you may not even be aware of some of the happenings outside your functional area.

Many of our clients are emerging companies striving towards their first clinical development program in anticipation of delivering on a promise to the patients they hope to serve. In most of these companies, leadership is appropriately focused on advancing the science and developing a “reason to believe” for both internal and external stakeholders (investigators, potential partners, investors, current and future employees, etc.).

What is the difference between strategic thinking in quantifying the future and Excel gymnastics? This was a distinction I needed to learn in my early years of marketing and, more specifically, market research.

When biopharma executives or business development leaders think about developing their “partnering story,” the focus is often on the innovation. That’s understandable. These are science-based organizations, and without question, the innovation is fundamental to the work.

When it comes to patient recruitment and retention for clinical trials, the bottom line is simply this: It is important and challenging in all scenarios… the difference is in how significant the focus and effort will need to be.

Last week, The NemetzGroup team met (virtually, of course!) to share insights from 2021 and how we could make 2022 even better. We broke into small Zoom groups, each of which was given 10 minutes to brainstorm on four topics:

In a recent internal planning session for Corval, our new cloud-based commercialization planning platform, we debated whether the term “Freedom to Lead” would resonate with our audience of early- to mid-stage biopharma companies.